AMB 051
Alternative Names: AMB 053; AMB-051; AMB-055; AMB-05X; AMG-820Latest Information Update: 26 Jul 2024
At a glance
- Originator Amgen
- Developer Amgen; AmMax Bio; LifeMax Laboratories
- Class Antibodies; Antifibrotics; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Urologics
- Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Giant cell tumour of tendon sheath; Idiopathic pulmonary fibrosis
- Phase I/II Solid tumours
- Preclinical Autosomal recessive polycystic kidney disease; Diabetic macular oedema; Unspecified; Wet age-related macular degeneration
Most Recent Events
- 03 Jun 2024 AmMax Bio completes a phase II trial for Giant cell tumour of tendon sheath in Australia, Netherlands and USA (EudraCT2022-000101-28) (NCT05349643)
- 24 May 2024 AmMax Bio terminates a phase II trial in Giant cell tumour of tendon sheath in Germany, Hungary, Poland, Ukraine, Netherlands, Czech Republic (IV) (NCT04938180) (EudraCT2020-004870-22)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Giant-cell-tumour-of-tendon-sheath in USA (IV)